Next Article in Journal
Downregulation of SHIP2 by Hepatitis B Virus X Promotes the Metastasis and Chemoresistance of Hepatocellular Carcinoma through SKP2
Next Article in Special Issue
Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors
Previous Article in Journal
Persistent Organic Pollutants and Breast Cancer: A Systematic Review and Critical Appraisal of the Literature
Previous Article in Special Issue
Prognostic Impact of Melatonin Receptors MT1 and MT2 in Non-Small Cell Lung Cancer (NSCLC)
Open AccessArticle

Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer

1
Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
2
X-ZELL, 133 Cecil Street, #06-02 Keck Seng Tower, Singapore 069535, Singapore
3
Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
4
Division of Urology, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
5
Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1064; https://doi.org/10.3390/cancers11081064
Received: 1 July 2019 / Revised: 21 July 2019 / Accepted: 24 July 2019 / Published: 27 July 2019
(This article belongs to the Special Issue New Biomarkers in Cancers)
Even though more than 350,000 men die from prostate cancer every year, broad-based screening for the disease remains a controversial topic. Guidelines demand that the only commonly accepted screening tool, prostate-specific antigen (PSA) testing, must be followed by prostate biopsy if results are elevated. Due to the procedure’s low positive predictive value (PPV), however, over 80% of biopsies are performed on healthy men or men with clinically insignificant cancer—prompting calls for new ways of vetting equivocal PSA readings prior to the procedure. Responding to the challenge, the present study investigated the diagnostic potential of tumour-associated circulating endothelial cells (tCECs), which have previously been described as a novel, blood-based biomarker for clinically significant cancers. Specifically, the objective was to determine the diagnostic accuracy of a tCEC-based blood test to detect clinically significant prostate cancer (defined as Gleason score ≥ 3 + 4) in high-risk patients. Performed in a blinded, prospective, single-centre set-up, it compared a novel tCEC index test with transrectal ultrasound-guided biopsy as a reference on a total of 170 patients and found that a tCEC add-on test will almost double the PPV of a standalone PSA test (32% vs. 17%; p = 0.0012), while retaining a negative predictive value above 90%. View Full-Text
Keywords: clinically significant prostate cancer; diagnostic accuracy; grey zone; liquid biopsy; PSA; tCEC; tumour-associated circulating endothelial cells; prostate cancer screening clinically significant prostate cancer; diagnostic accuracy; grey zone; liquid biopsy; PSA; tCEC; tumour-associated circulating endothelial cells; prostate cancer screening
Show Figures

Figure 1

MDPI and ACS Style

Bhakdi, S.C.; Suriyaphol, P.; Thaicharoen, P.; Grote, S.T.K.; Komoltri, C.; Chaiyaprasithi, B.; Charnkaew, K. Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer. Cancers 2019, 11, 1064.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop